Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Finished Goods (2016 - 2018)

Amicus Therapeutics' Finished Goods history spans 3 years, with the latest figure at $865000.0 for Q1 2018.

  • For the quarter ending Q1 2018, Finished Goods rose 284.44% year-over-year to $865000.0, compared with a TTM value of $865000.0 through Mar 2018, up 284.44%, and an annual FY2017 reading of $780000.0, up 622.22% over the prior year.
  • Finished Goods for Q1 2018 was $865000.0 at Amicus Therapeutics, up from $780000.0 in the prior quarter.
  • The five-year high for Finished Goods was $865000.0 in Q1 2018, with the low at $57000.0 in Q2 2016.
  • Average Finished Goods over 3 years is $337500.0, with a median of $207500.0 recorded in 2017.
  • Biggest YoY gain for Finished Goods was 622.22% in 2017; the steepest drop was 139.29% in 2017.
  • Tracing FOLD's Finished Goods over 3 years: stood at $108000.0 in 2016, then soared by 622.22% to $780000.0 in 2017, then increased by 10.9% to $865000.0 in 2018.
  • Per Business Quant, the three most recent readings for FOLD's Finished Goods are $865000.0 (Q1 2018), $780000.0 (Q4 2017), and $335000.0 (Q3 2017).